{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T10:26:10Z","timestamp":1773483970387,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["121S986"],"award-info":[{"award-number":["121S986"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10637-024-01473-9","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T07:01:52Z","timestamp":1726902112000},"page":"603-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"42","author":[{"given":"Seyda","family":"Gungordu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhan","family":"Aptullahoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,21]]},"reference":[{"issue":"16","key":"1473_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373(16):1541\u20131552","journal-title":"N Engl J Med"},{"issue":"6","key":"1473_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","volume":"12","author":"KG Roberts","year":"2015","unstructured":"Roberts KG, Mullighan CG (2015) Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol 12(6):344\u2013357","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1473_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrclinonc.2017.176","volume":"15","author":"DT Teachey","year":"2018","unstructured":"Teachey DT, Hunger SP (2018) Acute lymphoblastic leukaemia in 2017: immunotherapy for ALL takes the world by storm. Nat Rev Clin Oncol 15(2):69\u201370","journal-title":"Nat Rev Clin Oncol"},{"issue":"6381","key":"1473_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358(6381):15\u201316","journal-title":"Nature"},{"issue":"1","key":"1473_CR5","doi-asserted-by":"publisher","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2(1):a001008","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1473_CR6","doi-asserted-by":"crossref","unstructured":"Mullighan CG (2012) The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program, 2012: pp. 389\u2009\u2013\u200996","DOI":"10.1182\/asheducation.V2012.1.389.3798360"},{"issue":"3","key":"1473_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/ng.2532","volume":"45","author":"L Holmfeldt","year":"2013","unstructured":"Holmfeldt L et al (2013) The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45(3):242\u2013252","journal-title":"Nat Genet"},{"issue":"1","key":"1473_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/cdd.2009.68","volume":"17","author":"JC Marine","year":"2010","unstructured":"Marine JC, Lozano G (2010) Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 17(1):93\u2013102","journal-title":"Cell Death Differ"},{"issue":"5","key":"1473_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ccr.2013.03.013","volume":"23","author":"M Lu","year":"2013","unstructured":"Lu M et al (2013) Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1\/CDK1-phosphorylated nuclear iASPP. Cancer Cell 23(5):618\u2013633","journal-title":"Cancer Cell"},{"issue":"3","key":"1473_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1309\/AJCPLYU89XHSNHQO","volume":"141","author":"PL Ware","year":"2014","unstructured":"Ware PL et al (2014) MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: characterizing progression to high-grade tumors. Am J Clin Pathol 141(3):334\u2013341","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"1473_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1349-7006.1998.tb00552.x","volume":"89","author":"A Suzuki","year":"1998","unstructured":"Suzuki A et al (1998) Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res 89(2):221\u2013227","journal-title":"Jpn J Cancer Res"},{"issue":"6","key":"1473_CR12","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/blood.V85.6.1608.bloodjournal8561608","volume":"85","author":"M Zhou","year":"1995","unstructured":"Zhou M et al (1995) Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 85(6):1608\u20131614","journal-title":"Blood"},{"issue":"4","key":"1473_CR13","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/leu.2008.11","volume":"22","author":"L Gu","year":"2008","unstructured":"Gu L et al (2008) MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 22(4):730\u2013739","journal-title":"Leukemia"},{"key":"1473_CR14","doi-asserted-by":"crossref","unstructured":"Oliner JD, Saiki AY, Caenepeel S (2016) The role of MDM2 amplification and overexpression in Tumorigenesis. Cold Spring Harb Perspect Med, 6(6)","DOI":"10.1101\/cshperspect.a026336"},{"issue":"1","key":"1473_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molmed.2006.11.002","volume":"13","author":"LT Vassilev","year":"2007","unstructured":"Vassilev LT (2007) MDM2 inhibitors for cancer therapy. Trends Mol Med 13(1):23\u201331","journal-title":"Trends Mol Med"},{"issue":"5659","key":"1473_CR16","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844\u2013848","journal-title":"Science"},{"issue":"14","key":"1473_CR17","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1021\/jm400487c","volume":"56","author":"Q Ding","year":"2013","unstructured":"Ding Q et al (2013) Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 56(14):5979\u20135983","journal-title":"J Med Chem"},{"issue":"12","key":"1473_CR18","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.3324\/haematol.2018.206631","volume":"104","author":"C Ciardullo","year":"2019","unstructured":"Ciardullo C et al (2019) Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells. Haematologica 104(12):2429\u20132442","journal-title":"Haematologica"},{"issue":"4","key":"1473_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/bjc.2017.433","volume":"118","author":"CE Wu","year":"2018","unstructured":"Wu CE et al (2018) Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. Br J Cancer 118(4):495\u2013508","journal-title":"Br J Cancer"},{"issue":"26","key":"1473_CR20","doi-asserted-by":"publisher","first-page":"40115","DOI":"10.18632\/oncotarget.9499","volume":"7","author":"M Zanjirband","year":"2016","unstructured":"Zanjirband M, Edmondson RJ, Lunec J (2016) Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. Oncotarget 7(26):40115\u201340134","journal-title":"Oncotarget"},{"issue":"12","key":"1473_CR21","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1002\/ijc.32058","volume":"144","author":"L Chen","year":"2019","unstructured":"Chen L et al (2019) Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. Int J Cancer 144(12):3146\u20133159","journal-title":"Int J Cancer"},{"issue":"9","key":"1473_CR22","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","volume":"106","author":"K Kojima","year":"2005","unstructured":"Kojima K et al (2005) MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106(9):3150\u20133159","journal-title":"Blood"},{"key":"1473_CR23","doi-asserted-by":"crossref","unstructured":"Aptullahoglu E et al (2024) RNA sequencing reveals candidate genes and pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic lymphocytic leukemia. Biomedicines, 12(7)","DOI":"10.3390\/biomedicines12071388"},{"key":"1473_CR24","doi-asserted-by":"crossref","unstructured":"Daver NG et al (2023) Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial. Blood 141(11):1265\u20131276","DOI":"10.1182\/blood.2022016362"},{"issue":"5762","key":"1473_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1126\/science.1115035","volume":"311","author":"SA Lakhani","year":"2006","unstructured":"Lakhani SA et al (2006) Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311(5762):847\u2013851","journal-title":"Science"},{"issue":"6","key":"1473_CR26","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/sj.cdd.4401904","volume":"13","author":"KL Harms","year":"2006","unstructured":"Harms KL, Chen X (2006) The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ 13(6):890\u2013897","journal-title":"Cell Death Differ"},{"key":"1473_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-94-017-9211-0_13","volume":"85","author":"S Bohlman","year":"2014","unstructured":"Bohlman S, Manfredi JJ (2014) p53-independent effects of Mdm2. Subcell Biochem 85:235\u2013246","journal-title":"Subcell Biochem"},{"issue":"12","key":"1473_CR28","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1593\/neo.121534","volume":"14","author":"D Thomasova","year":"2012","unstructured":"Thomasova D et al (2012) p53-independent roles of MDM2 in NF-kappaB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia 14(12):1097\u20131101","journal-title":"Neoplasia"},{"issue":"1","key":"1473_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","volume":"15","author":"K Sabapathy","year":"2018","unstructured":"Sabapathy K, Lane DP (2018) Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Reviews Clin Oncol 15(1):13\u201330","journal-title":"Nat Reviews Clin Oncol"},{"issue":"2","key":"1473_CR30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.20517\/cdr.2022.113","volume":"6","author":"M Zanjirband","year":"2023","unstructured":"Zanjirband M, Rahgozar S, Aberuyi N (2023) Mir-16-5p enhances sensitivity to RG7388 through targeting expression (WIP1) in Childhood Acute Lymphoblastic Leukemia. Cancer Drug Resist 6(2):242\u2013256","journal-title":"Cancer Drug Resist"},{"issue":"14","key":"1473_CR31","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","volume":"100","author":"S Kato","year":"2003","unstructured":"Kato S et al (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100(14):8424\u20138429","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1473_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","volume":"29","author":"K Engeland","year":"2022","unstructured":"Engeland K (2022) Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ 29(5):946\u2013960","journal-title":"Cell Death Differ"},{"issue":"7A","key":"1473_CR33","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1101\/gad.7.7a.1126","volume":"7","author":"X Wu","year":"1993","unstructured":"Wu X et al (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7(7A):1126\u20131132","journal-title":"Genes Dev"},{"key":"1473_CR34","doi-asserted-by":"crossref","unstructured":"Aptullahoglu E et al (2023) SF3B1 mutations are Associated with Resistance to non-genotoxic MDM2 inhibition in chronic lymphocytic leukemia. Int J Mol Sci, 24(14)","DOI":"10.3390\/ijms241411335"},{"key":"1473_CR35","doi-asserted-by":"crossref","unstructured":"Lakoma A et al (2015) The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma. Cell Death Discov 1:15026","DOI":"10.1038\/cddiscovery.2015.26"},{"key":"1473_CR36","doi-asserted-by":"crossref","unstructured":"Qian S et al (2022) The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol 12:985363","DOI":"10.3389\/fonc.2022.985363"},{"issue":"11","key":"1473_CR37","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/ni1102-1013","volume":"3","author":"CA Benedict","year":"2002","unstructured":"Benedict CA, Norris PS, Ware CF (2002) To kill or be killed: viral evasion of apoptosis. Nat Immunol 3(11):1013\u20131018","journal-title":"Nat Immunol"},{"issue":"5","key":"1473_CR38","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"1","key":"1473_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3324\/haematol.10279","volume":"92","author":"U Testa","year":"2007","unstructured":"Testa U, Riccioni R (2007) Deregulation of apoptosis in acute myeloid leukemia. Haematologica 92(1):81\u201394","journal-title":"Haematologica"},{"key":"1473_CR40","doi-asserted-by":"crossref","unstructured":"Aptullahoglu E et al (2023) Splicing Modulation results in aberrant isoforms and Protein products of p53 pathway genes and the sensitization of B cells to non-genotoxic MDM2 inhibition. Int J Mol Sci, 24(3)","DOI":"10.3390\/ijms24032410"},{"issue":"41","key":"1473_CR41","doi-asserted-by":"publisher","first-page":"69779","DOI":"10.18632\/oncotarget.19266","volume":"8","author":"M Zanjirband","year":"2017","unstructured":"Zanjirband M et al (2017) Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. Oncotarget 8(41):69779\u201369796","journal-title":"Oncotarget"},{"key":"1473_CR42","doi-asserted-by":"crossref","unstructured":"Chamberlain V, Drew Y, Lunec J (2021) Tipping growth inhibition into apoptosis by combining treatment with MDM2 and WIP1 inhibitors in p53(WT) Uterine Leiomyosarcoma. Cancers (Basel), 14(1)","DOI":"10.3390\/cancers14010014"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01473-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01473-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01473-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T09:11:21Z","timestamp":1733562681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01473-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1473"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01473-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,21]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}